Colorectal Cancer Excellence Forum

Colorectal Cancer

Excellence Forum

Videos

Survival and Quality of Life Drive Treatment Preferences in Rectal Cancer

04/16/2026

Andrew Renehan, MD, PhD

Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.

Andrew Renehan, MD, PhD,...

04/16/2026

Oncology

Videos

HER2 Alterations Predict Inferior Survival With Anti-EGFR Therapy in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

03/11/2026

Davide Ciardiello, MD

Davide Ciardiello, MD, discusses exploratory findings from the CAPRI-2 GOIM trial assessing the clinical impact of HER2 alterations in patients with RAS/BRAFV600 wild-type, microsatellite-stable metastatic colorectal cancer receiving...

Davide Ciardiello, MD, discusses...

03/11/2026

Oncology

Videos

mFOLFOXIRI Plus Panitumumab Improves Overall Survival in RAS/BRAF Wild-Type mCRC

03/10/2026

Veronica Conca, MD

Veronica Conca, MD, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer.

Veronica Conca, MD, discusses...

03/10/2026

Oncology

Videos

Short-Course Radiotherapy Shows Immunologic Advantages in Locally Advanced Rectal Cancer

02/10/2026

Campbell Roxburgh, MD

Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.

Campbell Roxburgh, MD, discusses...

02/10/2026

Oncology

Videos

ctDNA-Guided Selection Optimizes Anti-EGFR Rechallenge in Metastatic Colorectal Cancer

01/29/2026

Stefania Napolitano, MD, PhD

Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.

Stefania Napolitano, MD, PhD,...

01/29/2026

Oncology

Videos

Anti-EGFR Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

01/29/2026

Stefania Napolitano, MD, PhD

Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.

Stefania Napolitano, MD, PhD,...

01/29/2026

Oncology

Videos

Encorafenib Plus Cetuximab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

01/16/2026

Scott Kopetz, MD, PhD

Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, discusses...

01/16/2026

Oncology

Videos

Encorafenib Plus Cetuximab and mFOLFOX6 for Patients With BRAF V600E-Mutated Metastatic Colorectal Cancer

09/10/2025

Scott Kopetz, MD, PhD

Scott Kopetz, MD, PhD, discusses results from the BREAKWATER study which demonstrated that encorafenib plus cetuximab and mFOLFOX6 improved survival outcomes compared to standard of care among previously untreated patients with BRAF...

Scott Kopetz, MD, PhD, discusses...

09/10/2025

Oncology

Videos

Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer

08/21/2025

John Strickler, MD

John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.

John Strickler, MD, discusses...

08/21/2025

Oncology

Conference Coverage

Use of ctDNA Monitoring During Colorectal Cancer Treatment to Identify Patients Eligible for Curative-Intent Metastasis-Directed Therapy

08/05/2025

Arvind Dasari, MD

Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.

Arvind Dasari, MD, discusses...

08/05/2025

Oncology

Recent News

FDA Alerts

Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer

05/04/2026

Stephanie Holland

Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...

Based on results from the phase...

05/04/2026

Oncology

FDA Approval

FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

05/01/2026

Emily Estrada

Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Based on results from the phase...

05/01/2026

Oncology

News

Varegacestat Advances Toward FDA Review in Desmoid Tumors

04/30/2026

Stephanie Holland

Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.

Based on results from the phase...

04/30/2026

Oncology

News

Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors

04/30/2026

Stephanie Holland

Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.

Results from a post hoc analysis...

04/30/2026

Oncology

News

FOG-001 Shows Early Activity in Patients With Desmoid Tumors

04/30/2026

Stephanie Holland

Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.

Results from a phase 1/2 study...

04/30/2026

Oncology

News

Bireociclib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer

04/30/2026

Emily Estrada

Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.

Final results from the phase 3...

04/30/2026

Oncology

News

Romiplostim Reduces the Need for Dose Modifications in Chemotherapy-Induced Thrombocytopenia

04/30/2026

Emily Estrada

Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.

Results from the phase 3 RECITE...

04/30/2026

Oncology

News

Tri-Weekly Cisplatin Matches Weekly Dosing With Better Tolerability in Cervical Cancer

04/30/2026

Stephanie Holland

Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.

Results from the phase 3 TACO...

04/30/2026

Oncology

FDA Alerts

FDA Grants Breakthrough Therapy Designation to TERN-701 in Ph-Positive Chronic Myeloid Leukemia

04/30/2026

Stephanie Holland

Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.

Based on data from the phase 1/2...

04/30/2026

Oncology

News

HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma

04/29/2026

Emily Estrada

Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.

Results from a phase 1 study...

04/29/2026

Oncology